Mizuho Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $20
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Mizuho analyst Anthony Petrone maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $24 to $20.
Mizuho analyst Anthony Petrone maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and lowers the price target from $24 to $20.